Micreos Proceeds to the finals at Ideas from EuropePublished: 28-11-2017
After a great performance at the Ideas from Europe semi-finals in Tallinn, Micreos was unanimously chosen by the jury to proceed to the finals! On top of this Micreos was also chosen by the public to be the most innovative idea in Europe. The finals will take place in the Ridderzaal in The Hague on the 24th April.
Above Mark Offerhaus’ presentation can be seen. Taking place at the semi-finals of Ideas from Europe 2017, Tallinn, Estonia: Bacteria are all around us.
Micreos develops the world’s first targeted antibacterial products, set to replace antibiotics. This unlocks a completely new approach in dealing with the bacteria around us and enables preventive daily therapy against only unwanted bacteria for as long as needed.
Micreos develops the world’s first targeted antibacterial products, set to replace antibiotics. With Micreos endolysin- and phage technology, for the first time it is possible to kill only the unwanted bacteria – including antibiotic resistant strains, such as MRSA – while preserving the beneficial bacteria, essential for our health.
Under the Gladskin brand Micreos Human Health has launched several creams and gels – available without prescription – for skin conditions such as eczema and inflammatory acne and rosacea. These have already had a life-changing impact for thousands of people (see: www.gladskin.com/reviews).
Under the Phageguard brand Micreos has also developed FDA-approved food safety products against Salmonella and Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised.
Micreos’ technology is applied in many areas, including human health, food safety, animal health and agriculture. Micreos Human Health is based in Bilthoven at the RIVM premises (Dutch NIH). Micreos Food Safety is based in Wageningen ‘Food Valley’ and member of the Food Valley Society. Micreos headquarters are based in The Hague, world capital of Peace and Justice.